vs

Side-by-side financial comparison of PROCEPT BioRobotics Corp (PRCT) and TRANSCAT INC (TRNS). Click either name above to swap in a different company.

TRANSCAT INC is the larger business by last-quarter revenue ($83.9M vs $83.1M, roughly 1.0× PROCEPT BioRobotics Corp). TRANSCAT INC runs the higher net margin — -1.3% vs -38.1%, a 36.7% gap on every dollar of revenue. On growth, TRANSCAT INC posted the faster year-over-year revenue change (25.6% vs 20.2%). Over the past eight quarters, PROCEPT BioRobotics Corp's revenue compounded faster (24.8% CAGR vs 8.7%).

PROCEPT BioRobotics Corp is a medical tech firm developing and commercializing robotic surgical solutions for urological care. Its flagship AquaBeam system provides image-guided minimally invasive therapy for benign prostatic hyperplasia, serving providers and patients across North America, Europe and global markets.

Transcat Inc is a leading provider of calibration and measurement compliance solutions, as well as a distributor of professional test and measurement instruments. It serves core sectors including life sciences, aerospace, industrial manufacturing, energy and utilities, with primary operations across the United States and Canada, helping clients meet regulatory and operational accuracy requirements.

PRCT vs TRNS — Head-to-Head

Bigger by revenue
TRNS
TRNS
1.0× larger
TRNS
$83.9M
$83.1M
PRCT
Growing faster (revenue YoY)
TRNS
TRNS
+5.4% gap
TRNS
25.6%
20.2%
PRCT
Higher net margin
TRNS
TRNS
36.7% more per $
TRNS
-1.3%
-38.1%
PRCT
Faster 2-yr revenue CAGR
PRCT
PRCT
Annualised
PRCT
24.8%
8.7%
TRNS

Income Statement — Q1 FY2026 vs Q3 FY2026

Metric
PRCT
PRCT
TRNS
TRNS
Revenue
$83.1M
$83.9M
Net Profit
$-31.6M
$-1.1M
Gross Margin
64.9%
30.1%
Operating Margin
-4.1%
0.1%
Net Margin
-38.1%
-1.3%
Revenue YoY
20.2%
25.6%
Net Profit YoY
-27.9%
-146.7%
EPS (diluted)
$-0.56
$-0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PRCT
PRCT
TRNS
TRNS
Q1 26
$83.1M
Q4 25
$76.4M
$83.9M
Q3 25
$83.3M
$82.3M
Q2 25
$79.2M
$76.4M
Q1 25
$69.2M
$77.1M
Q4 24
$68.2M
$66.8M
Q3 24
$58.4M
$67.8M
Q2 24
$53.4M
$66.7M
Net Profit
PRCT
PRCT
TRNS
TRNS
Q1 26
$-31.6M
Q4 25
$-29.8M
$-1.1M
Q3 25
$-21.4M
$1.3M
Q2 25
$-19.6M
$3.3M
Q1 25
$-24.7M
$4.5M
Q4 24
$-18.9M
$2.4M
Q3 24
$-21.0M
$3.3M
Q2 24
$-25.6M
$4.4M
Gross Margin
PRCT
PRCT
TRNS
TRNS
Q1 26
64.9%
Q4 25
60.6%
30.1%
Q3 25
64.8%
32.5%
Q2 25
65.4%
33.8%
Q1 25
63.9%
33.6%
Q4 24
64.0%
29.5%
Q3 24
63.2%
31.3%
Q2 24
59.0%
34.0%
Operating Margin
PRCT
PRCT
TRNS
TRNS
Q1 26
-4.1%
Q4 25
-40.6%
0.1%
Q3 25
-27.8%
4.3%
Q2 25
-28.0%
7.0%
Q1 25
-39.7%
9.0%
Q4 24
-28.9%
3.1%
Q3 24
-38.4%
5.5%
Q2 24
-50.3%
7.6%
Net Margin
PRCT
PRCT
TRNS
TRNS
Q1 26
-38.1%
Q4 25
-39.1%
-1.3%
Q3 25
-25.7%
1.5%
Q2 25
-24.7%
4.3%
Q1 25
-35.8%
5.8%
Q4 24
-27.6%
3.5%
Q3 24
-35.9%
4.8%
Q2 24
-48.0%
6.6%
EPS (diluted)
PRCT
PRCT
TRNS
TRNS
Q1 26
$-0.56
Q4 25
$-0.54
$-0.12
Q3 25
$-0.38
$0.14
Q2 25
$-0.35
$0.35
Q1 25
$-0.45
$0.49
Q4 24
$-0.34
$0.25
Q3 24
$-0.40
$0.35
Q2 24
$-0.50
$0.48

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PRCT
PRCT
TRNS
TRNS
Cash + ST InvestmentsLiquidity on hand
$245.6M
$3.5M
Total DebtLower is stronger
$51.7M
Stockholders' EquityBook value
$347.7M
$296.8M
Total Assets
$487.1M
$472.9M
Debt / EquityLower = less leverage
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PRCT
PRCT
TRNS
TRNS
Q1 26
$245.6M
Q4 25
$286.5M
$3.5M
Q3 25
$294.3M
$5.1M
Q2 25
$302.7M
$1.9M
Q1 25
$316.2M
$1.5M
Q4 24
$333.7M
$4.6M
Q3 24
$196.8M
$23.8M
Q2 24
$214.1M
$22.7M
Total Debt
PRCT
PRCT
TRNS
TRNS
Q1 26
$51.7M
Q4 25
$51.6M
Q3 25
$51.6M
Q2 25
$51.5M
Q1 25
$51.5M
Q4 24
$51.5M
Q3 24
$51.4M
Q2 24
$51.4M
Stockholders' Equity
PRCT
PRCT
TRNS
TRNS
Q1 26
$347.7M
Q4 25
$365.9M
$296.8M
Q3 25
$380.3M
$295.4M
Q2 25
$385.8M
$292.5M
Q1 25
$389.2M
$286.9M
Q4 24
$402.2M
$281.1M
Q3 24
$241.2M
$268.8M
Q2 24
$251.8M
$262.3M
Total Assets
PRCT
PRCT
TRNS
TRNS
Q1 26
$487.1M
Q4 25
$508.1M
$472.9M
Q3 25
$511.5M
$484.9M
Q2 25
$513.1M
$392.5M
Q1 25
$519.4M
$385.2M
Q4 24
$534.0M
$386.0M
Q3 24
$374.1M
$323.6M
Q2 24
$374.4M
$323.7M
Debt / Equity
PRCT
PRCT
TRNS
TRNS
Q1 26
0.15×
Q4 25
0.14×
Q3 25
0.14×
Q2 25
0.13×
Q1 25
0.13×
Q4 24
0.13×
Q3 24
0.21×
Q2 24
0.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PRCT
PRCT
TRNS
TRNS
Operating Cash FlowLast quarter
$12.1M
Free Cash FlowOCF − Capex
$9.5M
FCF MarginFCF / Revenue
11.3%
Capex IntensityCapex / Revenue
3.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$24.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PRCT
PRCT
TRNS
TRNS
Q1 26
Q4 25
$-10.3M
$12.1M
Q3 25
$-6.6M
$12.9M
Q2 25
$-15.0M
$3.6M
Q1 25
$-17.0M
$10.6M
Q4 24
$-32.4M
$12.6M
Q3 24
$-18.8M
$6.8M
Q2 24
$-15.7M
$8.9M
Free Cash Flow
PRCT
PRCT
TRNS
TRNS
Q1 26
Q4 25
$-12.2M
$9.5M
Q3 25
$-9.5M
$8.4M
Q2 25
$-17.8M
$-975.0K
Q1 25
$-18.8M
$7.9M
Q4 24
$-33.6M
$9.7M
Q3 24
$-19.0M
$2.9M
Q2 24
$-16.8M
$5.3M
FCF Margin
PRCT
PRCT
TRNS
TRNS
Q1 26
Q4 25
-15.9%
11.3%
Q3 25
-11.4%
10.3%
Q2 25
-22.5%
-1.3%
Q1 25
-27.2%
10.3%
Q4 24
-49.2%
14.6%
Q3 24
-32.6%
4.2%
Q2 24
-31.4%
7.9%
Capex Intensity
PRCT
PRCT
TRNS
TRNS
Q1 26
Q4 25
2.4%
3.2%
Q3 25
3.4%
5.4%
Q2 25
3.5%
6.0%
Q1 25
2.7%
3.5%
Q4 24
1.7%
4.3%
Q3 24
0.4%
5.8%
Q2 24
2.0%
5.5%
Cash Conversion
PRCT
PRCT
TRNS
TRNS
Q1 26
Q4 25
Q3 25
10.15×
Q2 25
1.11×
Q1 25
2.38×
Q4 24
5.34×
Q3 24
2.08×
Q2 24
2.02×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PRCT
PRCT

Handpieces and other consumables$43.0M52%
System sales and rentals$23.4M28%
Other$11.1M13%
Service$5.6M7%

TRNS
TRNS

Segment breakdown not available.

Related Comparisons